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The ~53 gene is well known as a tumour suppressor gene. In addition, the mutated ~53 gene is detected in a variety 
of human cancers including lung cancer, and is considered as an oncogene. Lung cancer is also frequently associated 
with interstitial lung diseases. Therefore, it may be possible to hypothesize that there might be some abnormality of 
~53 gene in interstitial lung diseases. This work examined the relationship between the ~53 protein and gene in lung 
tissues of 28 patients with interstitial lung diseases. Among 28 patients, 13 cases were pathologically diagnosed to 
have usual interstitial pneumonia (UIP), 12 cases were diagnosed as having collagen vascular lung diseases, and three 
cases were diagnosed to have a non-specific interstitial pneumonia. Twenty-three tissue samples were obtained by 
open lung biopsy and five samples were taken by autopsy. Paraffin-embedded tissues were treated by microwave, and 
stained with an anti-p53 antibody (D07) by the Avidin-Biotin-Peroxidase (ABC) method. In selected patients, 
mutations in exons 5-8 of the ~53 gene were also examined by single-strand conformation polymorphism (SSCP) 
analysis and DNA sequence. In addition, the presence of anti-p53 antibodies in patients’ sera was screened for by 
ELISA. Fifteen samples (53.6%) revealed overexpression of the ~53 protein in the nuclei of alveolar epithelial cells. 
However, SSCP or sequence analysis, which was performed in 13 tissues, showed no mutations in exons 5-8 of the 
~53 gene. In conclusion, ~53 proteins were overexpressed in interstitial lung diseases, and the expressed ~53 protein 
was considered to be wild-type. This wild-type ~53 protein may play a role in blocking the transformation of 
proliferative epithelial cells. 
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Introduction 
The ~53 gene is well known as a tumour suppressor gene, 
and a mutated ~53 gene is considered as an oncogene (l-6). 
When the 10 most frequent cancers world-wide are con- 
sidered, it is discovered that ~53 gene alterations are present 
in 40-50% of all patients (l-6). About 80% of ~53 
mutations are mis-sense mutations, with one amino acid 
substituted for another and consequent alteration of 
protein conformation (l-6). 
On the other hand, lung cancer is frequently complicated 
by interstitial lung disease (7). Therefore, it may be possible 
to hypothesize that there might be some abnormality ofp53 
gene in interstitial lung diseases. Thus, this study examined 
the ~53 protein and ~53 gene by immunohistochemical 
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method, single-strand conformation polymorphism (SSCP) 
analysis, direct sequence analysis, and anti-p53 antibodies 
measurement in the sera of patients with interstitial lung 
disease in order to determine the relationship among the 
~53 protein, gene and interstitial lung disease. 
Materials and Methods 
SAMPLES 
Twenty-eight specimens were collected from 28 patients 
with interstitial lung disease at Kagawa Medical University, 
Mitoyo General Hospital, Matsuyama Citizen Hospital 
and Kagawa Prefectural Central Hospital. Among 28 cases 
[14 male, 14 female, ranging from 39 to 75 years of age 
(mean 61.1)], 13 were diagnosed to have usual inter- 
stitial pneumonia (UIP). In this group, three cases were 
associated with lung cancer (one adenocarcinoma, one 
small cell carcinoma, and one squamous cell carcinoma), 12 
cases were diagnosed to have collagen vascular diseases 
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TABLE 1. Characteristics and clinical data of 28 patients entered in this study 
Case 
Age, Clinical 
sex diagnosis 
Pathological 
diagnosis 
History 
of dust 
exposure 
Smoking 
history 
Serum 
WBC 
W’) 
Serum 
CRP 
(mgdll’) 
Serum 
LDH 
@Jr’) 
1 39M 
2 51F 
3 65F 
4 75M 
5 76M 
6 67F 
7 44M 
8 14M 
9 5lM 
10 65M 
11 6lF 
12 73M 
13 14M 
14 51F 
15 68F 
16 IOM 
17 73F 
18 64F 
19 15M 
20 59F 
21 47F 
22 40F 
23 44F 
24 55F 
25 59F 
26 6lM 
27 66M 
28 69M 
IPF 
IPF 
IPF 
IPF+LC 
IPF 
IPF 
IPF 
IPF+LC 
IPF 
IPF 
IPF 
IPF 
IPF+LC 
RA 
RA 
RA 
RA 
RA 
RA 
RA 
DM 
DM 
DM 
DM 
PSS 
NSIP 
NSIP 
NSIP 
UIP 
UIP 
UIP 
UIP 
UIP 
UIP 
UIP 
UIP 
UIP 
UIP 
UIP 
UIP 
UIP 
RA lung 
RA lung 
RA lung 
RA lung 
RA lung 
RA lung 
RA lung 
DM lung 
DM lung 
DM lung 
DM lung 
PSS lung 
NSIP 
NSIP 
NSIP 
No 
No 
No 
No 
No 
No 
Yes (wood) 
No 
No 
No 
No 
No 
No 
No 
No 
Yes (metal) 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Smoker 16 200 
Non-smoker 5500 
Non-smoker 3200 
Non-smoker NE 
Non-smoker 13 300 
Non-smoker 3800 
Non- smoker 6300 
Smoker 1300 
Smoker 8300 
Smoker 9100 
Non-smoker 10 900 
Non-smoker NE 
Smoker 8100 
Non- smoker 8200 
Non-smoker NE 
Non- smoker 3100 
Non-smoker NE 
Non-smoker 1100 
Non- smoker 20100 
Non-smoker NE 
Non-smoker 6000 
Non-smoker 2500 
Smoker 2700 
Non- smoker 9600 
Non-smoker NE 
Smoker 9800 
Smoker 10 900 
Non-smoker 4600 
11.6 1296 
0.25 428 
0 384 
5.9 2149 
NE 469 
0.25 626 
0.43 214 
0.1 359 
0.6 381 
0.1 600 
4.1 328 
NE NE 
15.3 631 
2.33 284 
NE NE 
0.9 447 
NE NE 
1.6 808 
ME 462 
NE NE 
0.4 421 
0 1582 
2.1 460 
1.5 1068 
NE NE 
4.4 251 
21.1 441 
0.1 288 
DM, dermatomyositis; IPF, idiopathic pulmonary fibrosis; LC, lung cancer; NSIP, non-specific interstitial pneumonia; OLB, 
open lung biopsy; PSS, scleroderma; RA, rheumatoid arthritis; NE, not evaluated; IPF+LC, although lung cancer was 
complicated, only analysed in the area of UIP. 
consistent with a UIP pattern (seven cases of rheuma- 
toid arthritis, four cases of determatomyositis and one 
scleroderma), and three cases were diagnosed to have 
non-specific interstitial pneumonia (NSIP). Twenty-three 
tissues were taken by open lung biopsy and five samples 
were taken by autopsy. Patient characteristics and clinical 
data are shown in detail in Table 1. 
IMMUNOHISTOCHEMICAL METHOD 
These samples were foramalin-fixed and paraffin- 
embedded, treated by microwave and stained with DO1 (lot 
M7001, DAK0 JAPAN, Kyoto), an antibody that stains 
wild-type ~53 protein as well as the mutant type ~53 
protein, by the Avidin-Biotin-Peroxidase (ABC) method 
using a DAK0 LSAB kit (DAK0 JAPAN, Kyoto, Japan) 
(8). The intensity of the immunostain was scored as follows: 
+, more than 50% of the nuclei of regenerated epithelial 
cells were positive; f , less than 50% of the nuclei of 
regenerated epithelial cells were positive; - , no stain. 
SINGLE-STRAND CONFORMATION 
POLYMORPHISM (SSCP) ANALYSIS 
Since the frequent hot spot of ~53 mutations occurs in 
exons 5-8 in lung cancer (90%), (9), mutations in exons 5-8 
of the ~53 gene were also examined by SSCP analysis, a 
sensitive method for detection of ~5.3 gene mutations (8, 
10-12). Antibody positive staining was the main criteria 
used in selecting which cases were subjected to SSCP 
analysis when samples were available. For the 13 tissues 
selected (11 tissues were determined as ‘ +’ or ‘ If ‘, and two 
tissues were determined by ‘ - ‘), SSCP analysis was 
attempted. Thirteen tissues (11 tissues stained positive, and 
two tissues stained negative by DOI) were dewaxed with 
xylene, rinsed with ethanol, and vacuum desiccated. DNA 
was extracted by the phenol-chloroform method. Oligo- 
nucleotide primers were used to amplify each exon from 
exons 5 to 8 (Table 2) which were labelled by [r-“PI ATP. 
The conditions of polymerase chain reaction (PCR) were 
as follows: total volume 5.0~1 that contained 1.0~1 
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TABLE 2. PCR primers used to amplify from exons 5 to 8 of 
~53 gene 
Region Primer sequence 
Exon 5 5’-TTC CTC TTC CTG CAG TAC TC-3’ 
5’-GCC CCA GCT GCT CAC CAT CG-3’ 
Exon 6 5’-CAC TGA TTG CTC TTA GGT CTG-3’ 
5’-ACT TGC AAA CCA GAC CTC AG-3’ 
Exon 7 5’-GAG GCA AGC AGA GGC TGG-3’ 
5’-CCA AGG CGC ACT GGC CTC-3’ 
Exon 8 5’-CCT ATC CTG AGT AGT GGT AAT C-3’ 
5’-GTC CTG CTT GCT TAC CTC GC-3’ 
(0.1 ,ug ml ~ i) genomic DNA solution, 0.5~1 dNTP 
mixture (2.5 mM each dCTP, dGTP, dTTP, dATP), 0.5 ~1 
(50 PM) 32P-labelled primer (Table 2) and 0.5 U of Taq 
polymerase. After amplification, the reaction mixture for 
each exon was mixed with 95% formamide/ mmolll 
EDTA, which was heated to 80°C and applied to a 5% 
glycerol/S% polyacrylamide gel. Electrophoresis was 
performed, dried and autoradiographed. 
DIRECT SEQUENCE ANALYSIS 
DNA was extracted by the phenol-chloroform method. 
Oligonucleotide primers were used to amplify exon 5 in case 
14, and PCR was performed. PCR products were digested 
by the EcoR I restriction enzyme, ligated to vector and 
transfected to Escherichia coli. E. coli was cultured 
overnight and plasmid DNA was extracted. Then, this 
DNA was reacted with [y-32P]dCTP, and heated to 80°C. 
Electrophoresis was performed, and the gel was dried and 
autoradiographed. 
MEASUREMENT OF ANTI I’53 ANTIBODIES IN 
PATIENTS SERA 
In the 15 serum samples obtained from these 28 patients, 
the anti-p53 antibodies were measured using a p53- 
autoantibodies ELISA kit (Immunotech, U.S.A.). Results 
for the samples are expressed as negative and positive (low, 
medium and high) in comparison with the controls included 
in the kit (13). 
Results 
STAINING BY ANTI-P53 NUCLEAR PROTEIN 
ANTIBODY 
The examples of positive results of immunostaining by 
anti-p53 nuclear protein antibody are shown in Plates 1 
(case 23) and 2 (case 14). Overexpression of the p53 protein 
in the nucleus of the regenerated alveolar epithelium is 
shown in both plates. The nuclear immunostain of the 
neoformative epithelium in interstitial lung disease seemed 
PLATE 1. Example of positive staining (+) with anti-p53 
antibody (D07) by immunohistochemistry in interstitial 
pneumonia. Nuclear staining in the proliferating alveolar 
epithelial cells was detected occasionally, some revealing 
weak cytoplasmic positivity (arrows). 
PLATE 2. Example of positive immunostaining ( f ) with 
anti-p53 antibody (D07) in interstitial pneumonia. 
Nuclear staining in the proliferating alveolar epithelial 
cells was detected occasionally, some revealing 
cytoplasmic positivity (arrows). 
to be patchy. The summary of results of immunostain by 
anti-p53 nuclear protein antibody is shown in Table 3. 
Among the 28 tissues obtained from patients with inter- 
stitial lung disease, 10 tissues (35.7%) were determined to be 
p53 protein ‘+‘, five tissues (17.9%) to be p53 protein ‘ f ‘, 
and 13 tissues (46.4%) to be p53 protein ‘ - ‘. 
SSCP ANALYSIS OF P53 MUTATIONS 
Out of the 13 tissues, it was possible to get PCR products 
from nine tissues, but impossible to get PCR products from 
four tissues. Therefore, SSCP analysis was performed from 
exons 5 to 8 in nine tissues. The examples of the results of 
SSCP analysis are shown in Plate 3 (cases 2 and 14). There 
was no abnormal band compared to the normal control in 
case 2. So, it was suggested that no usual point mutation 
exists in exons 5 to 8 of the ~53 gene in case 2. The same 
results were obtained in the other seven tissues (cases 1, 3, 
16, 21, 26, 27 and 28). However, in case 14, an abnormal 
band appeared in exon 5, although no abnormal band was 
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TABLE 3. Summary of results of ~53 protein accumulation, p53 gene examination, and serum 
anti-p53 antibody 
Case 
Tissue 
origin 
p53 protein 
accumulation 
~53 gene 
examination 
Serum 
~53 antibody 
1 Autopsy 
2 OLB 
3 OLB 
4 Autopsy 
5 OLB 
6 OLB 
I OLB 
8 OLB 
9 OLB 
10 OLB 
11 OLB 
12 OLB 
13 Autopsy 
14 OLB 
15 Autopsy 
16 OLB 
17 OLB 
18 OLB 
19 OLB 
20 OLB 
21 OLB 
22 OLB 
23 Autopsy 
24 OLB 
25 OLB 
26 OLB 
21 OLB 
28 OLB 
+ 
+ 
+ 
+ 
+ 
It 
f 
f 
- 
- 
- 
- 
- 
+ 
+ 
It 
- 
- 
- 
- 
+ 
f 
- 
- 
- 
+ 
+ 
- 
Normal 
Normal 
Normal 
Impossible 
NE 
Impossible 
NE 
NE 
NE 
NE 
NE 
NE 
NE 
Normal 
Impossible 
Normal 
Impossible 
NE 
NE 
NE 
Normal 
NE 
NE 
NE 
NE 
Normal 
Normal 
Normal 
NE 
Negative 
Negative 
NE 
NE 
Low 
Negative 
Negative 
Low 
Negative 
Negative 
Negative 
NE 
Negative 
NE 
Negative 
NE 
NE 
NE 
NE 
NE 
NE 
Negative 
Negative 
NE 
NE 
Negative 
Negative 
NE, not evaluated; OLB, open lung biopsy. 
detected in exons 6-8. Therefore, the possibility of point 
mutation in exon 5 was suggested in this case. 
DIRECT SEQUENCE ANALYSIS 
Since point mutation of exon 5 was suggested in case 14 by 
SSCP analysis, direct sequencing of the PCR product was 
performed in this case. As a result, the DNA sequence of 
exon 5 in case 14 was the same as the normal ~53 exon 5 
gene (data not shown). Thus, although ~53 protein 
accumulated in tissues with interstitial lung disease, it was 
suggested that these accumulated ~53 nuclear proteins were 
wild-type. 
In the alveolar cell carcinoma which was used as a 
positive control, an abnormal band in exon 7 suggested 
point mutation. Direct sequencing was performed on exon 
7, and one point mutation at codon 234 was detected. 
ANTI-P53 ANTIBODY MEASUREMENT IN 
PATIENTS’ SERA 
Results of anti-p53 nuclear protein antibody in sera were 
expressed as values of absorption at OD450 nm. Values 
from 0.001 to 0.039 were considered to be negative, 
0.04-0.14 low, 0.15-0.29 medium, and values over 0.30 
were evaluated as high. In patients with interstitial lung 
disease, two (13.3%) samples were determined as low (case 
6 was 0.042, case 9 was 0.043) and 13 (86.7%) samples were 
considered to be negative. None of samples were considered 
to be medium or high (Table 1). 
Discussion 
In this study, immunostaining by anti-p53 protein antibody 
was performed, and the accumulation of ~53 protein in 
neoformative epithelial cells in interstitial lung diseases was 
demonstrated. 
The ~53 protein was discovered in the late 1970s as a 
cellular 53 kDa nuclear phosphoprotein bound to the 
large transforming antigen of the SV40 DNA virus (3). 
The ~53 gene encodes a nuclear protein which binds to 
and modulates the expression of genes important for 
DNA repair, cell division and cell death by apoptosis. The 
relationship of p53 alteration to tumour progression has 
been examined for many kinds of tumours, and frequent 
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Exon 5 Exon 6 Exon 5 Exon 6 
1 2 3 1 2 3 1 2 3 1 2 3 
- U’ :: 
N 
N 
P 
N 
P 
N N 
N 
‘P A i ,,I* ‘.i ” 2 _ ‘1‘ ’ ‘I, ,/ ,,F ,, “- 
,-:,s;v, 
Exon I Exon 8 Exon 7 Exon 8 
1 2 3 1 2 3 1 2 3 1 2 3 
(a) (b) 
PLATE 3. The results of SSCP analyses in exons 5-8 in (a) case 2 and (b) case 14. Lane 1: patient’s sample; Lane 2: 
positive control (in exon 5 at codon 139 AAG+AAT, in exon 6 at codon 189 GCC-+GTC, in exon 7 at codon 248 
CGG-CAG, in exon 8 at codon 270 TTT-tTTG); Lane 3: negative control (human placenta DNA). N: normal band, 
P: abnormal band in positive control, A: abnormal band of patient’s sample. In (a) there was no abnormal band 
compared to the negative control in this case. In (b), an abnormal band (A) of patient’s sample appeared in exon 5. 
Therefore, the possibility of point mutation in exon 5 was suggested in this case. 
association between p53 mutation and advanced stage of 
many tumour types has been found (3,5,6). 
Recent studies have indicated that ~53 alteration may 
occur as an early event in premalignant lesions. Detection 
of these alterations in surrounding normal, hyperplastic, 
metaplastic or dysplastic epithelium would further extend 
the timing of alteration to the pretransformation period (2). 
In addition, ~53 abnormalities, gene alteration and protein 
accumulation are frequently found in dysplastic lesions 
surrounding or adjacent to squamous cell carcinomas of the 
bronchus (2). Thus, ~53 alterations are very early events in 
tumourigenesis in many kinds of squamous cell carcinomas, 
including lung cancer. 
As lung cancer is frequently associated with interstitial 
lung disease (7), the authors hypothesized that some 
abnormality of the ~53 protein or ~53 gene may exist in 
interstitial lung disease. As a result, it was demonstrated 
that 15 (53.6%) of 28 samples revealed overexpression of 
the ~53 protein in the nuclei of epithelial cells. 
It seemed to be very important to clarify whether this 
overexpressed ~53 protein was wild-type or mutant-type. It 
has been reported that after damage to DNA by various 
agents, there is a transient elevation of wild-type ~53 
protein levels (1417). However, because the wild-type ~53 
protein has a relatively short half-life and is normally 
present in minute quantities in non-neoplastic cells (2) it is 
difficult to detect by immunohistochemical techniques. It 
has also been considered that if only a few nuclei are 
immunoreactive for a ~53 antibody that recognizes both the 
wild and mutant types of the ~53 protein, this pattern of 
focal immunostaining is probably due to the accumulation 
of the normal ~53 protein (18,19). In the present study, 
because immunopositivity of the ~53 protein in interstitial 
pneumonia was weak and patchy, the accumulated ~53 
protein appeared to be wild-type. 
To confirm this, SSCP analysis was performed in 13 
tissues. As the half-life of mutated ~53 protein fre- 
quently increased, mutated ~53 proteins were detected by 
immunohistochemistry. Therefore, in the present study, 
SSCP analysis was mainly performed in selected samples 
which showed ~53 stain ‘+’ as well as ~53 stain ‘ & ‘. To 
detect point mutation, SSCP analysis is a very sensitive 
method and is used routinely (8,10-12). However, in the 
present study, lung specimens obtained by open lung biopsy 
consisted of heterogeneous cells (for example, epithelial 
cells, mensenchymal cells and inAammatory cells). There- 
fore, SSCP analysis had some limitation to detect the point 
mutation of ~53 gene in specifically bronchoepithelial cells. 
Although it was impossible to perform SSCP analysis in 
four tissues, possibly due to the inhibition of PCR reaction 
in formalin-fixed paraffin-embedded tissue materials, there 
was no point mutation from exons 5 to 8 in the nine other 
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tissues. Therefore, the scattered accumulation of p53 pro- 
teins in the neoformative epithelium was considered to be 
wild-type. However, at present, the possibility that the 
accumulated p53 protein is mutant-type cannot be excluded 
because: (i) the authors only evaluated from exons 5 to 8; 
and (ii) the DNA was extracted from heterogeneous tissue, 
where epithelial cells, interstitial cells and inflammatory 
cells were mixed. 
In contrast, because manyp.53 gene mutations lead to the 
production of proteins which are significantly more stable 
than the wild-type (2,21,22), the accumulation of the p53 
protein is detectable by immunohistochemical methods. 
Therefore, high p53 protein levels in the nucleus have been 
considered to be derived from genetic changes (3). 
At present, assuming that the overexpressed p53 protein 
was determined to be wild-type, the clinical significance of 
the accumulated wild-type ~53 protein in interstitial lung 
diseases should be considered. 
It has been reported that ~53 expression was shown to be 
suppressed during the period active cellular proliferation in 
the injured tissue, and to re-emerge during the stages of 
healing (23). In contrast, mitogenic growth factors 
were expressed during the early phase of active cellular 
proliferation and they were suppressed upon healing (23). 
This inverse relationship between mitogenic growth factors 
and p53 suggests the presence of well-controlled physiologi- 
cal mechanisms that regulate, in viva. the processes of 
normal tissue repair in response to injury. At the stage of 
tissue regeneration, these mechanisms include both the 
expression of growth factors that promote cell proliferation 
and the suppression of p53 that downregulate proliferation. 
At the stage of healing, the expression of the mitogenic 
growth factors is suppressed and that of p53 re-emerges, 
reaching a peak at the time of complete epithelialization 
and healing of injured tissue (23). 
It has also been reported that as many as 60% of rapidly 
proliferating, non-neoplastic human lymphocytes express 
detectable levels of presumably wild-type p53 protein (2) 
(20). Rapidly proliferating tissues often contain a few cells 
with breaks in the DNA double helix, or with improperly 
assembled chromosomes before mitosis (1). DNA damage 
in somatic cells caused by either radiation or topoisomerase 
inhibitors leads to the increase of the wild-type p53 protein 
and arrests cells in the Gl phase of the cell cycle; the Gl 
phase is the period before DNA synthesis and mitosis, 
during which repair of breaks in DNA strands can proceed, 
thus reducing the probability of mutations (3,14). In 
addition, since p53 is an integral component of the pathway 
of programmed cell death (apoptosis) induced by DNA- 
damaging chemotherapeutic drugs or ionizing radiations, 
the accumulation of p53 could decrease both the pool of 
proliferating cells and the probability of their neoplastic 
transformations by inhibiting programmed cell death 
(3,24). Whether or not p53 causes reversible cell arrest or 
apotosis depends partly on the state of cellular activa- 
tion (25). Conflicting growth regulatory signals received 
during p53 induction, sustained p53 synthesis because of 
extensive unrepaired DNA damage, or ~53 activation after 
irreversible commitment to replication, all drive a cell to 
apoptosis (25). 
In interstitial lung diseases, when lung damage is strong, 
necrosis of bronchoepithelial cells takes place. In addition, 
when lung damage is not strong enough to cause necrosis, 
apoptotsis caused by increased levels of ~53 protein might 
take place in the healing process leading to lung fibrosis. In 
interstitial lung diseases, since metaplastic or dysplastic 
epithelial cells are frequently observed in the regenerated 
epithelium after tissue damage, it is speculated that DNA 
damage often occurs in the rapidly proliferating epithelial 
cells. With this background, the accumulated wild-type 
p53 proteins in the regenerated epithelium may block the 
transformation of proliferative cells and may induce 
apoptosis. 
The authors also evaluated the correlation of p53 
immunopositivity and clinical findings. In patients with 
UIP, the percentage of immunohistochemical positive 
cases (61.5%) seemed to be higher than that in collagen 
vascular disease (41.7%). Smoking and inhalation of dust 
did not influence p53 protein accumulation. In addition, 
there was no relation between p53 protein accumulation 
and clinical data (WBC count, CRP and LDH). Of three 
cases of UIP complicated with lung cancer (adenocarci- 
noma, small cell lung cancer and squamous cell carcinoma), 
two showed positive ~53 protein accumulation in the area 
of UIP. 
Serum antibodies against the p53 protein have been 
found in about 20% of patients with breast, lung and 
lymphoreticular cancers (13,26,27). As tumour-specific 
antigens, mutant p53 proteins may be a target of the host 
immune systems. So anti-p53 serum antibodies can be 
readily detected in a significant proportion of tumour 
samples. In this study, only two serum samples (cases 6 and 
9) gave positive results (however, the titers of anti-p53 
antibody were low). By immunostain, p53 protein accumu- 
lation in the neoformative epithelium was determined to be 
‘ i ’ in case 6 and ‘ - ’ in case 9. Therefore, no correlation 
seemed to exist between ~53 protein accumulation in the 
neoformative epithelium and p53 serum antibodies. Since 
p53 protein accumulation in the neoformative epithelium in 
patients with interstitial lung disease was considered to be 
wild-type, it was reasonable to assume that little or no 
anti-p53 antibodies existed in this study. 
In summary, the accumulation of wild-type p53 protein 
in bronchoepithelial cells in patients with interstitial pneu- 
monia was demonstrated in this study. Although the clini- 
cal significance of the accumulated ~53 protein was not 
clear, this wild-type ~53 protein may play a role in blocking 
the transformation of proliferative epithelial cells. 
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